The cost of bringing a drug to market has crossed $2 billion. The Phase 2 failure rate sits near 60%. […]

For IP counsel, portfolio managers, R&D leads, and institutional investors who need to move faster than the competition. Why Drug

1. The R&D Productivity Crisis: What the Numbers Actually Say The pharmaceutical industry’s core operating model has a compounding cost

Deconstructing the Middleman: Beyond the Textbook Definition To truly grasp the PBM’s role, we must look past the simple definition

1. The Scale of the Cliff: $236 Billion in Revenue at Risk Through 2030 The pharmaceutical industry is heading into

Generic drug companies fill more than 90% of all U.S. prescriptions and have saved the healthcare system an estimated $3.1

Section 1: The Regulatory Trinity: Anatomy of the Three Small-Molecule Pathways Why the Categorization Matters More Than Most Teams Think

1. What Pharmaceutical Portfolio Management Actually Is (and What Most Teams Get Wrong) Pharmaceutical portfolio management is the discipline of

How secondary pharmaceutical patents work, why they survive litigation, and what evergreening debates actually get wrong about post-approval R&D economics